Demographic data of pediatric patients examined after T-cell depleting therapy
| Patient no. . | Sex, age (y) . | Diagnosis . | Treatment modality . | Time of examination after therapy, mo . |
|---|---|---|---|---|
| 1 | Female, 8 | NB IV | HD-CTX/ASCR | 3, 9 |
| 2 | Female, 5 | RMS, relapsed | HD-CTX/ASCR | 3 |
| 3 | Male, 12 | MB, relapsed | HD-CTX/ASCR | 6 |
| 4 | Male, 11 | B-NHL IV | CTX | 3 |
| 5 | Female, 3 | Ependymoma | CTX | 1 |
| 6 | Male, 12 | ALL | CTX | 1 |
| 7 | Male, 11 | ALL | CTX | 1 |
| 8 | Female, 11 | SAA | allo-BMT (sibling) | 3 |
| 9 | Female, 16 | Osteosarcoma | CTX | 1 |
| 10 | Female, 12 | Ewing sarcoma | CTX | 1, 3, 6 |
| 11 | Male, 7 | ALL | allo-BMT (sibling) | 3 |
| 12 | Male, 15 | HD | CTX | 1 |
| 13 | Male, 14 | Osteosarcoma | CTX | 1 |
| 14 | Female, 6 | B-NHL IV | CTX | 3 |
| 15 | Male, 5 | Ewing sarcoma IV | HD-CTX/ASCR | 3, 6 |
| 16 | Female, 15 | Ovarian carcinoma | CTX | 3, 6 |
| 17 | Male, 8 | ALL, relapsed | allo-BMT (MUD) | 3 |
| 18 | Female, 12 | ALL | allo-BMT (MUD) | 3 |
| 19 | Female, 7 | AML | CTX | 1 |
| 20 | Female, 18 | Ewing sarcoma* | CTX | 1 |
| 21 | Male, 0.5 | NB IV | HD-CTX/ASCR | 1 |
| 22 | Male, 8 | β-thalassemia major | allo-BMT (MUD) | 3, 6 |
| Patient no. . | Sex, age (y) . | Diagnosis . | Treatment modality . | Time of examination after therapy, mo . |
|---|---|---|---|---|
| 1 | Female, 8 | NB IV | HD-CTX/ASCR | 3, 9 |
| 2 | Female, 5 | RMS, relapsed | HD-CTX/ASCR | 3 |
| 3 | Male, 12 | MB, relapsed | HD-CTX/ASCR | 6 |
| 4 | Male, 11 | B-NHL IV | CTX | 3 |
| 5 | Female, 3 | Ependymoma | CTX | 1 |
| 6 | Male, 12 | ALL | CTX | 1 |
| 7 | Male, 11 | ALL | CTX | 1 |
| 8 | Female, 11 | SAA | allo-BMT (sibling) | 3 |
| 9 | Female, 16 | Osteosarcoma | CTX | 1 |
| 10 | Female, 12 | Ewing sarcoma | CTX | 1, 3, 6 |
| 11 | Male, 7 | ALL | allo-BMT (sibling) | 3 |
| 12 | Male, 15 | HD | CTX | 1 |
| 13 | Male, 14 | Osteosarcoma | CTX | 1 |
| 14 | Female, 6 | B-NHL IV | CTX | 3 |
| 15 | Male, 5 | Ewing sarcoma IV | HD-CTX/ASCR | 3, 6 |
| 16 | Female, 15 | Ovarian carcinoma | CTX | 3, 6 |
| 17 | Male, 8 | ALL, relapsed | allo-BMT (MUD) | 3 |
| 18 | Female, 12 | ALL | allo-BMT (MUD) | 3 |
| 19 | Female, 7 | AML | CTX | 1 |
| 20 | Female, 18 | Ewing sarcoma* | CTX | 1 |
| 21 | Male, 0.5 | NB IV | HD-CTX/ASCR | 1 |
| 22 | Male, 8 | β-thalassemia major | allo-BMT (MUD) | 3, 6 |
NB IV indicates neuroblastoma, stage four; RMS, rhabdomyosarcoma; MB, medulloblastoma; B-NHL, B-cell non-Hodgkin lymphoma; ALL, acute lymphoblastic leukemia; SAA, severe aplastic anemia; HD, Hodgkin disease; AML, acute myelogenous leukemia; CTX, conventional high-dose chemotherapy; HD-CTX, high-dose chemotherapy; ASCR, autologous stem cell rescue; allo-BMT, allogeneic bone marrow transplantation; MUD, matched unrelated donor.
Second malignancy.